Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10210456 | 0.84 | KMT2A (0.65) | KMT2ASMN1; SMN2LMNAHTTEPHX2 | |
| SCHEMBL10612524 | 0.81 | KMT2A (0.61) | KMT2ASMN1; SMN2LMNAHTTEPHX2 | |
| SCHEMBL15467216 | 0.81 | KMT2A (0.61) | KMT2ASMN1; SMN2LMNAHTTEPHX2 | |
| SCHEMBL11057505 | 0.81 | LMNA (0.75) | KMT2ASMN1; SMN2LMNAHTTEPHX2 | |
| SCHEMBL10209768 | 0.81 | KMT2A (0.61) | KMT2ASMN1; SMN2LMNAHTTEPHX2 | |
| SCHEMBL14696521 | 0.78 | KMT2A (0.72) | KMT2ASMN1; SMN2LMNAHTTEPHX2 | |
| SCHEMBL25854709 | 0.75 | KMT2A (0.53) | KMT2ASMN1; SMN2LMNAHTTEPHX2 | |
| SCHEMBL11941699 | 0.75 | KMT2A (0.54) | KMT2ASMN1; SMN2LMNAHTTEPHX2 | |
| SCHEMBL14503293 | 0.73 | EPHX2 (0.67) | KMT2ASMN1; SMN2LMNAHTTEPHX2 | |
| SCHEMBL10746979 | 0.73 | KMT2A (0.64) | KMT2ASMN1; SMN2LMNAHTTEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11420944-B2 | Voltage-dependent t-type calcium channel blocker | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-08-23 | — | — | US | disclosed |
| US-20190077767-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL BLOCKER | NIPPON CHEMIPHAR CO., LTD. (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3404021-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL INHIBITOR | Nippon Chemiphar Co., Ltd. (JP) | 2018-11-21 | — | — | EP | disclosed |
| EP-0283310-B1 | N-BENZHYDRYL-SUBSTITUTED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION AND THEIR USE | Sankyo Company Limited (JP) | 1993-05-26 | — | — | EP | disclosed |
| US-5028610-A | Calcium Channel Blockers | SANKYO COMPANY LIMITED (JP) | 1991-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11420944-B2 | Voltage-dependent t-type calcium channel blocker | CACNA1I, CACNA1G, CACNA1E | KMT2A 1735/4885SMN1; SMN2 2060/4885LMNA 1556/4885 |
| US-20190077767-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL BLOCKER | CACNA1I, CACNA1G, CACNA1E | KMT2A 1648/4885SMN1; SMN2 1732/4885LMNA 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.